Upcoming events in the fall from 2cureX
August 18, 2021
We would like to keep our shareholders, customers and media updated on the company’s progress with a number of communication events in the coming fall.
Please save the dates and join us.
|2021-08-26||Q2 Interim Report released|
|2021-08-27 at 14:00 (CET)||Webinar: Presentation of the Q2 report by CEO Fernando Andreu, CFO Kenneth G. Johansen and CSO Ole Thastrup (participation by all shareholders. Registration link: https://www.2curex.com/2curex-webinar-registration-q2-2021/)|
|2021-09-15 at 15:00 (CET)||Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.|
|2021-09-28||Redeye Medtech & Diagnostics Investor meeting (Medtech & Diagnostics | Redeye)|
|2021-09-29||Mangold Investor Lunch (Save the Date – Mangold Insight investerarfrukost 29 september | Mangold Fondkommission AB)|
|2021-10-05 at 15:00 (CET)||Webinar: Clinical Peers (Dr. John Lindsay Marshall, from Georgetown University Hospital, US and Dr Jesús García-Foncillas, from University Hospital Fundación Jimenez Diaz, Madrid, Spain and Dr. Lars Henrik Jensen, University Hospital Vejle, DK) present the role of the functional test IndiTreat in personalized oncology to oncologists and 2cureX’s Distributors (promoted on Oncology Convention website, UK. Open participation. Details provided later|
|2021-10-12 at 13:00 (CET)||Webinar: Strategy Update Seminar (organized by Redeye). Open participation. Details provided later.|
|2021-10-21||Presentation by Henrik Harling (CMO 2cureX) at the 17. National Congress of Digestive Cancers (Viseu, Portugal) (17.º Congresso Nacional de Cancro Digestivo | FactorChave)|
|2021-11-25||Q3 Interim Report released|
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
Telephone: +45 2279 5399
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.
The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.
According to several published reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide1, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%2. Despite this, only one third of all cancer therapy decisions are currently supported by the result of an IVD.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, email@example.com